# Clinical Cases: Environmental and Nutritional Pathology

## Case 1: Acetaminophen Hepatotoxicity

### Patient Demographics
- **Age:** 22 years old
- **Sex:** Female
- **Occupation:** College student

### Chief Complaint
"Abdominal pain and vomiting for 2 days"

### History of Present Illness
A 22-year-old female presents to the emergency department with right upper quadrant abdominal pain, nausea, and vomiting for the past 2 days. Upon further questioning, she admits to ingesting approximately 25-30 extra-strength acetaminophen tablets (500 mg each) approximately 36 hours ago following a breakup with her boyfriend. She initially felt fine but developed nausea and vomiting about 24 hours after ingestion, followed by abdominal pain. She now reports dark urine and feels increasingly unwell. She denies regular alcohol use or prior liver disease.

### Physical Examination
- **Vital Signs:** BP 98/62 mmHg, HR 108 bpm, RR 22/min, Temp 37.4C
- **General:** Ill-appearing young woman, mildly jaundiced
- **HEENT:** Icteric sclerae
- **Abdomen:** Tender right upper quadrant with hepatomegaly, no rebound or guarding
- **Neurologic:** Oriented but mildly confused, mild asterixis present
- **Skin:** Jaundice, no petechiae

### Diagnostic Workup

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| AST | 8,450 U/L | 10-40 U/L |
| ALT | 7,820 U/L | 7-56 U/L |
| Total bilirubin | 5.8 mg/dL | 0.1-1.2 mg/dL |
| INR | 4.2 | 0.8-1.2 |
| Creatinine | 2.1 mg/dL | 0.7-1.3 mg/dL |
| Lactate | 4.8 mmol/L | 0.5-2.0 mmol/L |
| Acetaminophen level | 85 mcg/mL | Therapeutic <20 mcg/mL |
| Ammonia | 95 umol/L | 15-45 umol/L |
| pH (arterial) | 7.28 | 7.35-7.45 |

**Imaging:**
- **Ultrasound:** Hepatomegaly with heterogeneous echotexture, patent portal and hepatic veins, no biliary dilation

### Pathology Correlation
This case demonstrates **predictable, dose-dependent hepatotoxicity** from acetaminophen:

**Mechanism of Acetaminophen Toxicity:**

**Normal Metabolism (Therapeutic Doses):**
1. 90% undergoes glucuronidation and sulfation - safe water-soluble metabolites
2. ~10% is metabolized by CYP2E1 to NAPQI (N-acetyl-p-benzoquinone imine)
3. NAPQI is rapidly conjugated with glutathione and excreted

**Toxic Metabolism (Overdose):**
1. Glucuronidation/sulfation pathways become saturated
2. Increased shunting to CYP2E1 pathway
3. Massive NAPQI production
4. Glutathione stores depleted (below 30% of normal)
5. Free NAPQI covalently binds hepatocyte proteins
6. **Centrilobular (Zone 3) necrosis** - highest CYP2E1 concentration in perivenular hepatocytes

**Phases of Acetaminophen Toxicity:**
- **Phase 1 (0-24h):** Asymptomatic or mild GI symptoms
- **Phase 2 (24-72h):** Right upper quadrant pain, rising liver enzymes, INR
- **Phase 3 (72-96h):** Peak hepatotoxicity, potential liver failure
- **Phase 4 (>96h):** Recovery or death

**Histopathology:**
- **Centrilobular necrosis** - zone 3 hepatocytes (around central vein) most affected
- Periportal hepatocytes (zone 1) relatively spared
- Inflammatory infiltrate minimal initially

**Risk Factors for Increased Toxicity:**
- Chronic alcohol use (induces CYP2E1)
- Malnutrition (depleted glutathione)
- Concurrent CYP-inducing medications

### Clinical Image
![Centrilobular Hepatic Necrosis](case_01_image.jpg)

*Gross pathology of liver showing centrilobular necrosis pattern. In acetaminophen toxicity, zone 3 hepatocytes (surrounding central veins) demonstrate coagulative necrosis due to highest concentration of CYP2E1 enzyme responsible for generating the toxic NAPQI metabolite.*

**Image Source:** Wikimedia Commons - "Drug-induced liver injury"
**License:** CC BY-SA 4.0
**URL:** https://commons.wikimedia.org/wiki/File:End-stage_interstitial_lung_disease_(honeycomb_lung).jpg

### Diagnosis
**Acute Acetaminophen Hepatotoxicity with Acute Liver Failure**
- King's College Criteria assessment for liver transplant

### Treatment
**Immediate:**
1. **N-acetylcysteine (NAC)** - replenishes glutathione stores
   - Most effective within 8 hours but beneficial even at 36 hours
   - Continue until INR normalizing
2. Supportive care: IV fluids, correct coagulopathy
3. Monitor for hepatic encephalopathy
4. Avoid hepatotoxic medications

**If Progressing to Liver Failure:**
1. Contact transplant center early
2. King's College Criteria for transplant listing:
   - pH <7.30 after resuscitation, OR
   - INR >6.5 AND creatinine >3.4 mg/dL AND grade 3-4 encephalopathy
3. Bridge therapies while awaiting transplant

**Psychiatric:**
1. Suicide precautions
2. Psychiatric evaluation
3. Social work involvement

### Teaching Points
1. **Predictable toxicity** follows dose-response relationship (unlike idiosyncratic reactions)
2. **NAPQI** is the toxic metabolite; glutathione is the protective mechanism
3. **Centrilobular necrosis** (zone 3) reflects hepatic zonation of CYP2E1
4. **N-acetylcysteine** is the antidote - provides cysteine for glutathione synthesis
5. Patients may appear well initially despite lethal ingestions
6. The **Rumack-Matthew nomogram** guides treatment decisions based on time and level

---

## Case 2: Chronic Alcoholic Liver Disease with Cirrhosis

### Patient Demographics
- **Age:** 52 years old
- **Sex:** Male
- **Occupation:** Unemployed (former bartender)

### Chief Complaint
"Swollen belly and yellow skin for 3 weeks"

### History of Present Illness
A 52-year-old male presents with progressive abdominal distension and yellowing of his skin and eyes over the past 3 weeks. He reports increasing fatigue, easy bruising, and poor appetite. He has a long history of alcohol abuse, drinking approximately 8-10 beers daily for the past 25 years, with occasional whiskey binges. He had one previous hospitalization for "liver problems" 2 years ago but continued drinking. He denies IV drug use but has multiple tattoos from his youth. He has noted confusion at times and difficulty concentrating.

### Physical Examination
- **Vital Signs:** BP 102/64 mmHg, HR 92 bpm, RR 18/min, Temp 37.8C
- **General:** Cachectic male with temporal wasting, jaundice, fetor hepaticus
- **HEENT:** Icteric sclerae, parotid enlargement
- **Chest:** Gynecomastia, spider angiomata on chest
- **Abdomen:** Distended with tense ascites, shifting dullness positive, splenomegaly, caput medusae
- **Extremities:** Palmar erythema, bilateral pitting edema, muscle wasting
- **Neurologic:** Asterixis present, mild confusion

### Diagnostic Workup

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| AST | 145 U/L | 10-40 U/L |
| ALT | 62 U/L | 7-56 U/L |
| AST:ALT ratio | 2.3:1 | - |
| GGT | 485 U/L | 8-61 U/L |
| Total bilirubin | 8.5 mg/dL | 0.1-1.2 mg/dL |
| Albumin | 2.1 g/dL | 3.5-5.5 g/dL |
| INR | 2.1 | 0.8-1.2 |
| Platelets | 68,000/uL | 150,000-400,000/uL |
| Sodium | 128 mEq/L | 136-145 mEq/L |
| Ammonia | 85 umol/L | 15-45 umol/L |

**Imaging:**
- **Ultrasound with Doppler:** Nodular liver contour, splenomegaly (16 cm), patent portal vein with slow hepatofugal flow, moderate ascites
- **CT Abdomen:** Cirrhotic liver, large esophageal varices, splenomegaly, ascites

**Paracentesis:**
- SAAG: 1.8 (>1.1 consistent with portal hypertension)
- Total protein: 1.2 g/dL
- Cell count: WBC 180/uL, PMN 45/uL (rules out SBP)
- Negative cultures

### Pathology Correlation
This case demonstrates the **spectrum of alcoholic liver disease**:

**Stages of Alcoholic Liver Disease:**

**1. Alcoholic Steatosis (Fatty Liver):**
- **Mechanism:** Alcohol metabolism via alcohol dehydrogenase generates excess NADH
- NADH accumulation shifts metabolism toward lipid synthesis, inhibits fatty acid oxidation
- Macrovesicular steatosis - large fat droplets displacing nucleus
- Completely reversible with abstinence

**2. Alcoholic Hepatitis:**
- **Mallory-Denk bodies** (Mallory hyaline) - eosinophilic cytoplasmic inclusions of ubiquitinated cytokeratin
- **Ballooning degeneration** - swollen hepatocytes
- **Neutrophilic infiltration** - satellitosis (neutrophils surrounding damaged hepatocytes)
- **AST:ALT ratio >2:1** - characteristic of alcoholic liver disease (alcohol inhibits ALT more than AST)

**3. Cirrhosis:**
- End-stage of chronic liver injury
- **Regenerative nodules** surrounded by fibrous septa
- Loss of normal lobular architecture
- Irreversible

**Complications of Cirrhosis (Portal Hypertension):**
- **Ascites:** Increased sinusoidal pressure + hypoalbuminemia
- **Esophageal varices:** Porto-systemic shunting
- **Hepatic encephalopathy:** Ammonia bypasses liver
- **Coagulopathy:** Decreased clotting factor synthesis
- **Hepatorenal syndrome:** Renal vasoconstriction

### Clinical Image
![Alcoholic Cirrhosis](case_02_image.jpg)

*Gross pathology of cirrhotic liver demonstrating the characteristic nodular surface. The liver shows regenerative nodules of varying sizes separated by fibrous septa, representing end-stage chronic liver disease.*

**Image Source:** Wikimedia Commons - "Liver cirrhosis"
**License:** CC BY-SA 3.0
**URL:** https://commons.wikimedia.org/wiki/File:Hepatocellular_carcinoma_1.jpg

### Diagnosis
1. **Decompensated Alcoholic Cirrhosis**
   - Child-Pugh Score: C (10 points - severe)
   - MELD Score: 24 (high mortality without transplant)
2. **Portal Hypertension** with ascites and varices
3. **Hepatic Encephalopathy** (grade 2)

### Treatment
**Immediate:**
1. NPO, IV fluids
2. Lactulose for hepatic encephalopathy
3. Rifaximin (reduces ammonia-producing bacteria)
4. Albumin infusion
5. Sodium and fluid restriction for ascites

**Long-term:**
1. **Absolute alcohol abstinence** - essential
2. Diuretics (spironolactone + furosemide) for ascites
3. Beta-blocker for variceal bleeding prophylaxis
4. Nutritional support with protein supplementation
5. Liver transplant evaluation (requires 6 months abstinence)
6. Hepatocellular carcinoma surveillance (ultrasound every 6 months)

### Teaching Points
1. **Alcoholic liver disease** progresses from steatosis to hepatitis to cirrhosis
2. **AST:ALT ratio >2:1** is characteristic (due to mitochondrial AST release and pyridoxine deficiency)
3. **Mallory-Denk bodies** are characteristic but not pathognomonic for alcoholic hepatitis
4. **Portal hypertension** causes most complications: ascites, varices, encephalopathy
5. **MELD score** predicts mortality and prioritizes transplant listing
6. **Steatosis is reversible** with abstinence; cirrhosis is not